Theodoric Wong

Theodoric Wong

Auto-generated profile, based on publicly available information

Theodoric Wong

Department of Paediatric Gastroenterology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
DGDaniela Gattini
Daniela Gattini
ARAmin J. Roberts
Amin J. Roberts
PWPaul W. Wales
Paul W. Wales
SBSue V. Beath
Sue V. Beath
HEHelen M. Evans
Helen M. Evans
YAYaron Avitzur
Yaron Avitzur

14 July 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
ARAmin J. Roberts
Amin J. Roberts
PWPaul W. Wales
Paul W. Wales
SBSue V. Beath
Sue V. Beath
HEHelen M. Evans
Helen M. Evans
JHJonathan Hind
Jonathan Hind
YAYaron Avitzur
Yaron Avitzur
Deciding which patients would benefit from intestinal transplantation (IT) remains an ethical/clinical dilemma. New criteria* were proposed in 2015: ≥2 intensive care unit (ICU) admissions, loss of ≥3 central venous catheter (CVC) sites, and persistently elevated conjugated bilirubin (CB ≥ 75 μmol/L) despite 6 weeks of lipid modification strategies. We performed a retrospective, international, multicenter validation study of 443 children (61% male, median gestational age 34 weeks [IQR 29-37]), diagnosed with IF between 2010 and 2015. Primary outcome measure was death or IT. Sensitivity, specificity, NPV, PPV, and probability of death/transplant (OR, 95% confidence intervals) were calculated for each criterion. Median age at IF diagnosis was 0.1 years (IQR 0.03-0.14) with median follow-up of 3.8 years (IQR 2.3-5.3). Forty of 443 (9%) patients died, 53 of 443 (12%) were transplanted; 11 died posttransplant. The validated criteria had a high predictive value of death/IT; ≥2 ICU admissions (p < .0001, OR 10.2, 95% CI 4.0-25.6), persistent CB ≥ 75 μmol/L (p < .0001, OR 8.2, 95% CI 4.8-13.9). and loss of ≥3 CVC sites (p = .0003, OR 5.7, 95% CI 2.2-14.7). This large, multicenter, international study in a contemporary cohort confirms the validity of the Toronto criteria. These validated criteria should guide listing decisions in pediatric IT.

7 August 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
GHgil hardy
gil hardy
TWTheodoric Wong
Theodoric Wong
HMHana Morrissey
Hana Morrissey
CACollin Anderson
Collin Anderson
SMSissel J. Moltu
Sissel J. Moltu
PBPatrick Anthony Ball
Patrick Anthony Ball
Introduction: Micronutrients (vitamins and trace elements) are essential to all nutrition. For children and neonates who are dependent upon nutrition support therapies for growth and development, the prescribed regimen must supply all essential components. This paper aims to facilitate interpretation of existing clinical guidelines into practical approaches for the provision of micronutrients in pediatric parenteral nutrition.Methods: An international, interdisciplinary expert panel was convened to review recent evidence‐based guidelines and published literature to develop consensus‐based recommendations on practical micronutrient provision in pediatric parenteral nutrition.Results: The guidelines and evidence have been interpreted as answers to 10 commonly asked questions around the practical principles for provision and monitoring of micronutrients in pediatric patients.Conclusion: Micronutrients are an essential part of all parenteral nutrition and should be included in the pediatric nutrition therapy care plan.

21 October 2022 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
PDF file
AAAndre Cardoso Almeida
Andre Cardoso Almeida
CSClare Skerritt
Clare Skerritt
ECEden Cooper
Eden Cooper
AWAnthony Wiskin
Anthony Wiskin
TWTheodoric Wong
Theodoric Wong
IJIngo Jester
Ingo Jester